Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma
Background The impact of neoadjuvant chemoradiotherapy (nCRT) on early stage esophageal cancer is unknown. Here, we compared the outcomes after esophagectomy alone or nCRT plus surgery for clinically staged node‐negative esophageal cancer. Methods We searched the Surveillance, Epidemiology, and End...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-09-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13586 |
id |
doaj-4cf3e02e1396483d86770d1b88f356fb |
---|---|
record_format |
Article |
spelling |
doaj-4cf3e02e1396483d86770d1b88f356fb2020-11-25T03:16:29ZengWileyThoracic Cancer1759-77061759-77142020-09-011192618262910.1111/1759-7714.13586Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinomaHui‐Jiang Gao0Yu‐Cheng Wei1Lei Gong2Nan Ge3Bin Han4Guo‐Dong Shi5Zhen‐Tao Yu6Department of Thoracic Surgery The Affiliated Hospital of Qingdao University Qingdao ChinaDepartment of Thoracic Surgery The Affiliated Hospital of Qingdao University Qingdao ChinaDepartment of Esophageal Cancer, Tianjin's Clinical Research Center for Cancer and Key Laboratory of Cancer Prevention and Therapy Tianjin Medical University Cancer Institute and Hospital Tianjin ChinaDepartment of Thoracic Surgery The Affiliated Hospital of Qingdao University Qingdao ChinaDepartment of Thoracic Surgery The Affiliated Hospital of Qingdao University Qingdao ChinaDepartment of Thoracic Surgery The Affiliated Hospital of Qingdao University Qingdao ChinaDepartment of Esophageal Cancer, Tianjin's Clinical Research Center for Cancer and Key Laboratory of Cancer Prevention and Therapy Tianjin Medical University Cancer Institute and Hospital Tianjin ChinaBackground The impact of neoadjuvant chemoradiotherapy (nCRT) on early stage esophageal cancer is unknown. Here, we compared the outcomes after esophagectomy alone or nCRT plus surgery for clinically staged node‐negative esophageal cancer. Methods We searched the Surveillance, Epidemiology, and End Results database for patients with clinically node‐negative (cN0) esophageal cancer from 2004 to 2016 who underwent surgery alone or nCRT plus surgery. Propensity score matching and Cox regression analysis were used to identify covariates associated with overall survival and cancer‐specific survival. Results A total of 1587 patients were retrospectively identified, of whom 49.8% (n = 791) received nCRT and 80.2% (n = 1273) were truly node‐negative diseases. For the entire cohort, surgery alone was associated with a statistically significant but modest absolute increase in survival outcomes (P < 0.01). After matching, nCRT was associated with improved five‐year overall survival for pT3‐4N0 (localized) disease (59.6% vs. 37.7%; P < 0.001) and pathological node‐positive disease (60.5% vs. 40.7%; P = 0.002). Cox multivariate regression analysis revealed that the addition of nCRT for truly node‐negative patients with tumor length ≥ 3 cm, pT1‐2N0 (early‐staged) and localized disease were independent risk factors for survival than surgery alone (P < 0.01). Conclusions Compared with surgery alone, patients with cN0 esophageal cancer with pathological node‐positive or localized true node‐negative disease gain a significant survival benefit from nCRT. However, nCRT plus surgery was associated with decreased survival for early‐staged true node‐negative patients. This finding may have significant implications on the use of neoadjuvant chemoradiation in patients with cN0 disease.https://doi.org/10.1111/1759-7714.13586Esophageal carcinomaesophagectomyneoadjuvant chemoradiotherapysurvival |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hui‐Jiang Gao Yu‐Cheng Wei Lei Gong Nan Ge Bin Han Guo‐Dong Shi Zhen‐Tao Yu |
spellingShingle |
Hui‐Jiang Gao Yu‐Cheng Wei Lei Gong Nan Ge Bin Han Guo‐Dong Shi Zhen‐Tao Yu Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma Thoracic Cancer Esophageal carcinoma esophagectomy neoadjuvant chemoradiotherapy survival |
author_facet |
Hui‐Jiang Gao Yu‐Cheng Wei Lei Gong Nan Ge Bin Han Guo‐Dong Shi Zhen‐Tao Yu |
author_sort |
Hui‐Jiang Gao |
title |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma |
title_short |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma |
title_full |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma |
title_fullStr |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma |
title_full_unstemmed |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma |
title_sort |
neoadjuvant chemoradiotherapy plus surgery versus surgery alone for clinical node‐negative esophageal carcinoma |
publisher |
Wiley |
series |
Thoracic Cancer |
issn |
1759-7706 1759-7714 |
publishDate |
2020-09-01 |
description |
Background The impact of neoadjuvant chemoradiotherapy (nCRT) on early stage esophageal cancer is unknown. Here, we compared the outcomes after esophagectomy alone or nCRT plus surgery for clinically staged node‐negative esophageal cancer. Methods We searched the Surveillance, Epidemiology, and End Results database for patients with clinically node‐negative (cN0) esophageal cancer from 2004 to 2016 who underwent surgery alone or nCRT plus surgery. Propensity score matching and Cox regression analysis were used to identify covariates associated with overall survival and cancer‐specific survival. Results A total of 1587 patients were retrospectively identified, of whom 49.8% (n = 791) received nCRT and 80.2% (n = 1273) were truly node‐negative diseases. For the entire cohort, surgery alone was associated with a statistically significant but modest absolute increase in survival outcomes (P < 0.01). After matching, nCRT was associated with improved five‐year overall survival for pT3‐4N0 (localized) disease (59.6% vs. 37.7%; P < 0.001) and pathological node‐positive disease (60.5% vs. 40.7%; P = 0.002). Cox multivariate regression analysis revealed that the addition of nCRT for truly node‐negative patients with tumor length ≥ 3 cm, pT1‐2N0 (early‐staged) and localized disease were independent risk factors for survival than surgery alone (P < 0.01). Conclusions Compared with surgery alone, patients with cN0 esophageal cancer with pathological node‐positive or localized true node‐negative disease gain a significant survival benefit from nCRT. However, nCRT plus surgery was associated with decreased survival for early‐staged true node‐negative patients. This finding may have significant implications on the use of neoadjuvant chemoradiation in patients with cN0 disease. |
topic |
Esophageal carcinoma esophagectomy neoadjuvant chemoradiotherapy survival |
url |
https://doi.org/10.1111/1759-7714.13586 |
work_keys_str_mv |
AT huijianggao neoadjuvantchemoradiotherapyplussurgeryversussurgeryaloneforclinicalnodenegativeesophagealcarcinoma AT yuchengwei neoadjuvantchemoradiotherapyplussurgeryversussurgeryaloneforclinicalnodenegativeesophagealcarcinoma AT leigong neoadjuvantchemoradiotherapyplussurgeryversussurgeryaloneforclinicalnodenegativeesophagealcarcinoma AT nange neoadjuvantchemoradiotherapyplussurgeryversussurgeryaloneforclinicalnodenegativeesophagealcarcinoma AT binhan neoadjuvantchemoradiotherapyplussurgeryversussurgeryaloneforclinicalnodenegativeesophagealcarcinoma AT guodongshi neoadjuvantchemoradiotherapyplussurgeryversussurgeryaloneforclinicalnodenegativeesophagealcarcinoma AT zhentaoyu neoadjuvantchemoradiotherapyplussurgeryversussurgeryaloneforclinicalnodenegativeesophagealcarcinoma |
_version_ |
1724635918249230336 |